Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
Cellular Oncology

16-05-2024 | Hepatocellular Carcinoma | Research

SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma

Published in: Cellular Oncology

Login to get access

Abstract

Purpose

Chronic hepatitis B virus (HBV) infection is the primary risk factor for the malignant progression of hepatocellular carcinoma (HCC). It has been reported that HBV X protein (HBx) possesses oncogenic properties, promoting hepatocarcinogenesis and chemoresistance. However, the detailed molecular mechanisms are not fully understood. Here, we aim to investigate the effects of miR-128-3p/SPG21 axis on HBx-induced hepatocarcinogenesis and chemoresistance.

Methods

The expression of SPG21 in HCC was determined using bioinformatics analysis, quantitative real-time PCR (qRT-PCR), western blotting, and immunohistochemistry (IHC). The roles of SPG21 in HCC were elucidated through a series of in vitro and in vivo experiments, including real-time cellular analysis (RTCA), matrigel invasion assay, and xenograft mouse model. Pharmacologic treatment and flow cytometry were performed to demonstrate the potential mechanism of SPG21 in HCC.

Results

SPG21 expression was elevated in HCC tissues compared to adjacent non-tumor tissues (NTs). Moreover, higher SPG21 expression correlated with poor overall survival. Functional assays revealed that SPG21 fostered HCC tumorigenesis and invasion. MiR-128-3p, which targeted SPG21, was downregulated in HCC tissues. Subsequent analyses showed that HBx amplified TRPM7-mediated calcium influx via miR-128-3p/SPG21, thereby activating the c-Jun N-terminal kinase (JNK) pathway. Furthermore, HBx inhibited doxorubicin-induced apoptosis by engaging the JNK pathway through miR-128-3p/SPG21.

Conclusion

The study suggested that SPG21, targeted by miR-128-3p, might be involved in enhancing HBx-induced carcinogenesis and doxorubicin resistance in HCC via the TRPM7/Ca2+/JNK signaling pathway. This insight suggested that SPG21 could be recognized as a potential oncogene, offering a novel perspective on its role as a prognostic factor and a therapeutic target in the context of HCC.
Appendix
Available only for authorised users
Literature
1.
H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Ca-Cancer J. Clin. 71, 209–249 (2021)PubMedCrossRef
2.
W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015. Ca-Cancer J. Clin. 66, 115–132 (2016)PubMedCrossRef
3.
D. Du, C. Liu, M. Qin, X. Zhang, T. Xi, S. Yuan, H. Hao, J. Xiong, Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm. Sin B 12, 558–580 (2022)PubMedCrossRef
4.
H.B. El-Serag, Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142, 1264–1273 (2012)PubMedCrossRef
5.
C. Zheng, M. Liu, Y. Ge, Y. Qian, H. Fan, HBx increases chromatin accessibility and ETV4 expression to regulate dishevelled-2 and promote HCC progression. Cell. Death Dis. 13, 116 (2022)PubMedPubMedCentralCrossRef
6.
W. Wei, W. Huang, Y. Pan, F. Zhu, J. Wu, Functional switch of viral protein HBx on cell apoptosis, transformation, and tumorigenesis in association with oncoprotein Ras. Cancer Lett. 244, 119–128 (2006)PubMedCrossRef
7.
C. Wang, M.D. Wang, P. Cheng, H. Huang, W. Dong, W.W. Zhang, P.P. Li, C. Lin, Z.Y. Pan, M.C. Wu, W.P. Zhou, Hepatitis B virus X protein promotes the stem-like properties of OV6(+) cancer cells in hepatocellular carcinoma. Cell. Death Dis. 8, e2560 (2017)
8.
K.J. Su, Y.L. Yu, Downregulation of SHIP2 by Hepatitis B Virus X Promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2. Cancers. 11 (2019)
9.
X. Lin, S. Zuo, R. Luo, Y. Li, G. Yu, Y. Zou, Y. Zhou, Z. Liu, Y. Liu, Y. Hu, Y. Xie, W. Fang, Z. Liu, HBX-induced miR-5188 impairs FOXO1 to stimulate beta-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. Theranostics. 9, 7583–7598 (2019)PubMedPubMedCentralCrossRef
10.
M.A. Popescu, D. Patriche, M.O. Dobrica, A.M. Pantazica, A.P. Flintoaca, Y. Rouille, C.I. Popescu, Branza-Nichita, Sac1 phosphatidylinositol 4-phosphate phosphatase is a novel host cell factor regulating hepatitis B virus particles assembly and release. Febs J. 289, 7486–7499 (2022)PubMedCrossRef
11.
Y.Y. Li, K. Kuroki, T. Shimakami, K. Murai, K. Kawaguchi, T. Shirasaki, K. Nio, S. Sugimoto, T. Nishikawa, H. Okada, N. Orita, H. Takayama, Y. Wang, B.P. Thi, A. Ishida, S. Iwabuchi, S. Hashimoto, T. Shimaoka, N. Tabata, M. Watanabe-Takahashi, K. Nishikawa, H. Yanagawa, M. Seiki, K. Matsushima, T. Yamashita, S. Kaneko, M. Honda, Hepatitis B Virus utilizes a Retrograde trafficking Route via the Trans-Golgi Network to avoid lysosomal degradation. Cell. Mol. Gastroenterol. Hepatol. 15, 533–558 (2023)PubMedCrossRef
12.
F. Arnesano, G. Natile, Interference between copper transport systems and platinum drugs. Semin Cancer Biol. 76, 173–188 (2021)PubMedCrossRef
13.
M.A. Simpson, H. Cross, C. Proukakis, A. Pryde, R. Hershberger, A. Chatonnet, M.A. Patton, A.H. Crosby, Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia. Am. J. Hum. Genet. 73, 1147–1156 (2003)PubMedPubMedCentralCrossRef
14.
L. Zeitlmann, P. Sirim, E. Kremmer, W. Kolanus, Cloning of ACP33 as a novel intracellular ligand of CD4. J. Biol. Chem. 276, 9123–9132 (2001)PubMedCrossRef
15.
M.C. Hanna, C. Blackstone, Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1. Neurogenetics. 10, 217–228 (2009)PubMedPubMedCentralCrossRef
16.
17.
M. Wang, F. Yu, X. Chen, P. Li, K. Wang, The underlying mechanisms of noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. Mol. Ther. -Nucl Acids. 21, 13–27 (2020)CrossRef
18.
X.C. Wei, Y.R. Xia, P. Zhou, X. Xue, S. Ding, L.J. Liu, F. Zhu, Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J. Gastroenterol. 27, 8302–8322 (2021)PubMedPubMedCentralCrossRef
19.
C.Y. Huang, X.P. Huang, J.Y. Zhu, Z.G. Chen, X.J. Li, X.H. Zhang, S. Huang, J.B. He, F. Lian, Y.N. Zhao, G.B. Wu, Mir-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. Oncol. Rep. 33, 2889–2898 (2015)PubMedCrossRef
20.
R. Zhong, J. Tian, M. Fu, S. Ma, L. Liu, J. Li, N. Shen, J. Ke, Y. Yang, Y. Gong, Y. Zhu, Y. Wang, J. Gong, J. Chang, P. Lei, X. Cheng, K. Huang, G. Shen, X. Miao, LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk. Oncogene. 39, 1944–1956 (2020)PubMedCrossRef
21.
Q. Wu, W. Wu, B. Fu, L. Shi, X. Wang, K. Kuca, JNK signaling in cancer cell survival. Med. Res. Rev. 39, 2082–2104 (2019)PubMedCrossRef
22.
Y.T. Lin, Y.C. Liu, C.C. Chao, Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin. Biochem. Pharmacol. 122, 80–89 (2016)PubMedCrossRef
23.
Y. Liu, L. Liu, Y. Zhou, P. Zhou, Q. Yan, X. Chen, S. Ding, F. Zhu, CKLF1 enhances inflammation-mediated carcinogenesis and prevents Doxorubicin-Induced apoptosis via IL6/STAT3 signaling in HCC. Clin. Cancer Res. 25, 4141–4154 (2019)PubMedCrossRef
24.
B.L. Bennett, D.T. Sasaki, B.W. Murray, E.C. O’Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S.S. Bhagwat, A.M. Manning, D.W. Anderson, SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98, 13681–13686 (2001)
25.
Z. Fang, H. Xu, J. Duan, B. Ruan, J. Liu, P. Song, J. Ding, C. Xu, Z. Li, K. Dou, L. Wang, Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice. Signal. Transduct. Target. Ther. 8, 94 (2023)PubMedPubMedCentralCrossRef
26.
K. Clark, M. Langeslag, B. van Leeuwen, L. Ran, A.G. Ryazanov, C.G. Figdor, W.H. Moolenaar, K. Jalink, F.N. van Leeuwen, TRPM7, a novel regulator of actomyosin contractility and cell adhesion. Embo J. 25, 290–301 (2006)PubMedPubMedCentralCrossRef
27.
R. Zhou, Y. Chen, S. Li, X. Wei, W. Hu, S. Tang, J. Ding, W. Fu, H. Zhang, F. Chen, W. Hao, Y. Lin, R. Zhu, K. Wang, L. Dong, Y. Zhao, X. Feng, F. Chen, C. Ding, W. Hu, TRPM7 channel inhibition attenuates rheumatoid arthritis articular chondrocyte ferroptosis by suppression of the PKCalpha-NOX4 axis. Redox Biol. 55, 102411 (2022)PubMedPubMedCentralCrossRef
28.
M.R. Zanotelli, J. Zhang, C.A. Reinhart-King, Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell. Metab. 33, 1307–1321 (2021)PubMedPubMedCentralCrossRef
29.
Q. Jiang, N. Zheng, L. Bu, X. Zhang, X. Zhang, Y. Wu, Y. Su, L. Wang, X. Zhang, S. Ren, X. Dai, D. Wu, W. Xie, W. Wei, Y. Zhu, J. Guo, SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. Mol. Cancer. 20, 100 (2021)PubMedPubMedCentralCrossRef
30.
P. Qian, A. Banerjee, Z.S. Wu, X. Zhang, H. Wang, V. Pandey, W.J. Zhang, X.F. Lv, S. Tan, P.E. Lobie, T. Zhu, Loss of SNAIL regulated mir-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res. 72, 6036–6050 (2012)PubMedCrossRef
31.
B. Su, T. Luo, J. Zhu, J. Fu, X. Zhao, L. Chen, H. Zhang, Y. Ren, L. Yu, X. Yang, M. Wu, G. Feng, S. Li, Y. Chen, H. Wang, Interleukin-1beta/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis. Hepatology. 61, 585–597 (2015)PubMedCrossRef
32.
M.S. Han, T. Barrett, M.A. Brehm, R.J. Davis, Inflammation mediated by JNK in myeloid cells promotes the development of Hepatitis and Hepatocellular Carcinoma. Cell. Rep. 15, 19–26 (2016)PubMedPubMedCentralCrossRef
33.
J. Li, Z.Q. Hu, S.Y. Yu, L. Mao, Z.J. Zhou, P.C. Wang, Y. Gong, S. Su, J. Zhou, J. Fan, S.L. Zhou, X.W. Huang, CircRPN2 inhibits aerobic glycolysis and metastasis in Hepatocellular Carcinoma. Cancer Res. 82, 1055–1069 (2022)PubMedCrossRef
34.
Y. Yang, P. Ren, X. Liu, X. Sun, C. Zhang, X. Du, B. Xing, PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition. J. Exp. Clin. Cancer Res. 41, 101 (2022)PubMedPubMedCentralCrossRef
35.
Q. Zhang, G. Song, L. Yao, Y. Liu, M. Liu, S. Li, H. Tang, miR-3928v is induced by HBx via NF-kappaB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3. J. Exp. Clin. Cancer Res. 37, 14 (2018)PubMedPubMedCentralCrossRef
36.
J.C. Casciano, M.J. Bouchard, Hepatitis B virus X protein modulates cytosolic ca(2+) signaling in primary human hepatocytes. Virus Res. 246, 23–27 (2018)PubMedCrossRef
37.
A.M. Meredith, C.R. Dass, Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J. Pharm. Pharmacol. 68, 729–741 (2016)PubMedCrossRef
38.
L. Liu, Z. Lv, M. Wang, D. Zhang, D. Liu, F. Zhu, HBV enhances Sorafenib Resistance in Hepatocellular Carcinoma by reducing ferroptosis via SRSF2-Mediated abnormal PCLAF splicing. Int. J. Mol. Sci. 24 (2023)
39.
L. Liu, X. Chen, S. Xie, C. Zhang, Z. Qiu, F. Zhu, Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology. 56, 1760–1769 (2012)PubMedCrossRef
40.
Y. Zhou, L. Liu, Y. Liu, P. Zhou, Q. Yan, H. Yu, X. Chen, F. Zhu, Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell. Death Discov. 7, 177 (2021)PubMedPubMedCentralCrossRef
41.
K. Mao, J. Zhang, C. He, K. Xu, J. Liu, J. Sun, G. Wu, C. Tan, Y. Zeng, J. Wang, Z. Xiao, Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 352, 245–252 (2014)PubMedCrossRef
42.
W. Song, C. Zheng, M. Liu, Y. Xu, Y. Qian, Z. Zhang, H. Su, X. Li, H. Wu, P. Gong, Y. Li, H. Fan, TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Mol. Ther. 29, 2601–2616 (2021)PubMedPubMedCentralCrossRef
43.
L.J. Liu, Z. Lv, X. Xue, Z.Y. Xing, F. Zhu, Canonical WNT signaling activated by WNT7B contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by inhibiting Mitophagy. Cancers 14 (2022)
44.
S. Gupta, S. Bent, J. Kohlwes, Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 139, 46–50 (2003)PubMedCrossRef
45.
L.J. Liu, J.M. Liao, F. Zhu, Proliferating cell nuclear antigen clamp associated factor, a potential proto-oncogene with increased expression in malignant gastrointestinal tumors. World J. Gastrointest. Oncol. 13, 1425–1439 (2021)PubMedPubMedCentralCrossRef
46.
47.
C. Soderblom, J. Stadler, H. Jupille, C. Blackstone, O. Shupliakov, M.C. Hanna, Targeted disruption of the mast syndrome gene SPG21 in mice impairs Hind limb function and alters axon branching in cultured cortical neurons. Neurogenetics. 11, 369–378 (2010)PubMedPubMedCentralCrossRef
48.
Y. Li, Y. Fu, X. Hu, L. Sun, D. Tang, N. Li, F. Peng, X.G. Fan, The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell. Death Dis. 10, 405 (2019)PubMedPubMedCentralCrossRef
49.
D. Yu, B. Green, A. Marrone, Y. Guo, S. Kadlubar, D. Lin, J. Fuscoe, I. Pogribny, B. Ning, Suppression of CYP2C9 by microRNA hsa-mir-128-3p in human liver cells and association with hepatocellular carcinoma. Sci. Rep. 5, 8534 (2015)PubMedPubMedCentralCrossRef
50.
B. Zhang, S. Han, B. Feng, X. Chu, L. Chen, R. Wang, Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. Exp. Mol. Med. 49, e293 (2017)
51.
S.J. Zhou, Y.L. Deng, H.F. Liang, J.C. Jaoude, F.Y. Liu, Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and notch signaling in hepatocellular carcinoma. Cell. Death Differ. 24, 1577–1587 (2017)PubMedPubMedCentralCrossRef
52.
M.J. Chen, D.W. Wu, C.J. Shen, Y.M. Cheng, C.C. Wu, H. Lee, Hepatitis B virus X protein promotes tumor invasion and poor prognosis in hepatocellular carcinoma via phosphorylation of paxillin at serine 178 by activation of the c-Jun NH2-terminal kinase. Am. J. Cancer Res. 10, 275–283 (2020)PubMedPubMedCentral
53.
S. Lin, K. Hoffmann, C. Gao, M. Petrulionis, I. Herr, P. Schemmer, Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J. Pineal Res. 62 (2017)
54.
Z. Yang, H. Zhang, M. Yin, Z. Cheng, P. Jiang, M. Feng, B. Liao, Z. Liu, Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways. Int. J. Biol. Sci. 18, 5963–5977 (2022)PubMedPubMedCentralCrossRef
55.
T. Sakurai, S. Maeda, L. Chang, M. Karin, Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. U. S. A. 103, 10544–10551 (2006)
56.
L. Hui, K. Zatloukal, H. Scheuch, E. Stepniak, E.F. Wagner, Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118, 3943–3953 (2008)PubMedPubMedCentralCrossRef
57.
J. Vakkila, M.T. Lotze, Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4, 641–648 (2004)PubMedCrossRef
58.
N. Fausto, Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis. 19, 243–252 (1999)PubMedCrossRef
59.
L.T. Su, H.C. Chen, O. Gonzalez-Pagan, J.D. Overton, J. Xie, L. Yue, L.W. Runnels, TRPM7 activates m-calpain by stress-dependent stimulation of p38 MAPK and c-Jun N-terminal kinase. J. Mol. Biol. 396, 858–869 (2010)PubMedPubMedCentralCrossRef
60.
Z. Zeng, T. Leng, X. Feng, H. Sun, K. Inoue, L. Zhu, Z.G. Xiong, Silencing TRPM7 in mouse cortical astrocytes impairs cell proliferation and migration via ERK and JNK signaling pathways. Plos One 10, e0119912 (2015)
61.
62.
Y. Chen, Y. Yu, S. Sun, Z. Wang, P. Liu, S. Liu, J. Jiang, Bradykinin promotes migration and invasion of hepatocellular carcinoma cells through TRPM7 and MMP2. Exp. Cell. Res. 349, 68–76 (2016)CrossRef
63.
S. Voringer, L. Schreyer, W. Nadolni, M.A. Meier, K. Woerther, C. Mittermeier, S. Ferioli, S. Singer, K. Holzer, S. Zierler, V. Chubanov, B. Liebl, T. Gudermann, S. Muehlich, Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity. Oncogene. 39, 2328–2344 (2020)PubMedCrossRef
64.
E.H. Yousef, E.N. Abo, G.A. El, Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7. Life Sci. 324, 121735 (2023)PubMedCrossRef
65.
S. Owatari, S. Akune, M. Komatsu, R. Ikeda, S.D. Firth, X.F. Che, M. Yamamoto, K. Tsujikawa, M. Kitazono, T. Ishizawa, T. Takeuchi, T. Aikou, J.F. Mercer, S. Akiyama, T. Furukawa, Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 67, 4860–4868 (2007)PubMedCrossRef
66.
G.V. Kalayda, C.H. Wagner, I. Buss, J. Reedijk, U. Jaehde, Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. Bmc Cancer. 8, 175 (2008)PubMedPubMedCentralCrossRef
67.
C. Zhao, R. Guo, F. Guan, S. Ma, M. Li, J. Wu, X. Liu, H. Li, B. Yang, MicroRNA-128-3p enhances the chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Sci. Rep. 10, 9471 (2020)PubMedPubMedCentralCrossRef
68.
X. Xu, W. Jiang, P. Han, J. Zhang, L. Tong, X. Sun, MicroRNA-128-3p mediates Lenvatinib Resistance of Hepatocellular Carcinoma cells by downregulating c-Met. J. Hepatocell Carcinoma. 9, 113–126 (2022)PubMedPubMedCentralCrossRef
69.
J. Cai, L. Fang, Y. Huang, R. Li, X. Xu, Z. Hu, L. Zhang, Y. Yang, X. Zhu, H. Zhang, J. Wu, Y. Huang, J. Li, M. Zeng, E. Song, Y. He, L. Zhang, M. Li, Simultaneous overactivation of Wnt/beta-catenin and TGFbeta signalling by mir-128-3p confers chemoresistance-associated metastasis in NSCLC. Nat. Commun. 8, 15870 (2017)PubMedPubMedCentralCrossRef
70.
X. Feng, H. Liu, Z. Zhang, Y. Gu, H. Qiu, Z. He, Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 36, 123 (2017)PubMedPubMedCentralCrossRef
71.
M. Ashenden, A. van Weverwijk, N. Murugaesu, A. Fearns, J. Campbell, Q. Gao, M. Iravani, C.M. Isacke, An in vivo functional screen identifies JNK Signaling as a modulator of chemotherapeutic response in breast Cancer. Mol. Cancer Ther. 16, 1967–1978 (2017)PubMedCrossRef
Metadata
Title
SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma
Publication date
16-05-2024
Published in
Cellular Oncology
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-024-00955-5